NCT05208242View on ClinicalTrials.gov

Strong Albumin Solutions in Patients With Septic Shock

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

February 28, 2026

Conditions
SepsisSeptic ShockShock, Toxic
Interventions
DRUG

hyperoncotic human albumin solution

20% human albumin solution (presented in 100ml glass bottles)

DRUG

Buffered crystalloid solutions

Buffered crystalloids solutions for all intravenous fluid therapy

Trial Locations (2)

M13 9WL

RECRUITING

Manchester Royal Infirmary, Manchester

M23 9LT

NOT_YET_RECRUITING

Wythenshawe Hospital, Manchester

All Listed Sponsors
collaborator

University of Manchester

OTHER

lead

Manchester University NHS Foundation Trust

OTHER_GOV